retatrutide regulatory approval Extreme Side Effects Followed Overdose of Unapproved Weight-Loss Drug Retatrutide, an experimental weight-loss drug,

Not for diagnostic, therapeutic, or consumer applications

April 16, 2026: Ozempic & GLP-1 MDL Passes 3,500 Cases The number of lawsuits in a federal MDL alleging severe gastrointestinal side effects from taking GLP-1s like Ozempic has climbed to 3,546

Patients should always follow the specific instructions provided with their prescribed medication and consult their GP or pharmacist if uncertain

Who Should Consider Prescription GLP-1 Options Over OTC Alternatives Individuals with BMI over 27, metabolic syndrome, prediabetes, or type 2 diabetes have the strongest clinical evidence supporting prescription GLP-1 therapy